The global peptide CDMO market is projected to reach $13.4 billion by 2034, growing at a compound annual rate of approximately 10%, with GLP-1 manufacturing accounting for a growing share
L., Davies, M., et al (2022)
Smartphone monitoring halves avoidable cirrhosis readmissions in randomized trial by Doug Brunk Digital tool paired with caregiver engagement lowered 30-day rehospitalizations among patients with cirrhosis in a multicenter trial
Receptor potency: Extra nine-amino-acid tail boosts binding affinity
Future trials should therefore include body-composition assessment, muscle strength testing, physical performance measures, and rehabilitation adherence as core outcomes, rather than focusing only on body weight and pain ( 7.3 Perioperative management before arthroplasty Although current perioperative guidance emphasizes individualized assessment of GLP-1 receptor agonist use, KOA-specific perioperative pathways have not yet been established ( 7.4 Structural disease modification remains unproven in humans Perhaps the most important scientific limitation is that symptomatic improvement should not yet be interpreted as proof of structural disease modification
Staying healthy is crucial for everyone but its not that easy either
